Prosecution Insights
Last updated: April 19, 2026

Examiner: ZHU, JIANJIAN

Tech Center 1600 • Art Units: 1631 1699

This examiner grants 62% of resolved cases

Performance Statistics

62.2%
Allow Rate
+2.2% vs TC avg
144
Total Applications
+82.0%
Interview Lift
1339
Avg Prosecution Days
Based on 74 resolved cases, 2023–2026

Rejection Statute Breakdown

3.3%
§101 Eligibility
18.0%
§102 Novelty
32.9%
§103 Obviousness
27.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17778611 T-CELL MASTER CELL BANK Final Rejection Takeda Pharmaceutical Company Limited
18416749 METHODS FOR SCREENING GENETIC PERTURBATIONS Final Rejection The Regents of the University of California
17511187 CHIMERIC ANTIGEN RECEPTOR (CAR) NK CELLS AND USES THEREOF Non-Final OA RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
17819064 CD40L EXPRESSING MAMMALIAN CELLS AND THEIR USE Final Rejection Hoffmann-La Roche Inc.
18941862 BIOACTIVE AND ANTIOXIDANT SUPRAMOLECULAR POLYMER HYDROGELS FOR NEURAL CELL CULTURE Non-Final OA Northwestern University
17429540 BIOFUNCTIONALIZED HYDROGEL FOR CELL CULTURE Final Rejection Vanderbilt University
17770585 ENGINEERED NATURAL KILLER CELLS AND METHODS FOR USING THE SAME IN IMMUNOTHERAPY AND AUTOPHAGY INHIBITON TECHNIQUES Final Rejection Purdue Research Foundation
18026474 CELL SUPPORT AND METHOD OF PRODUCING SAME, CELL CULTURE METHOD AND CELL STRUCTURE Non-Final OA Konica Minolta, Inc.
17757503 T-CELL DEATH ASSOCIATED GENE 8 (TDAG8) MODULATION TO ENHANCE CELLULAR CANCER THERAPIES Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17549028 PHYSIOLOGIC GROWTH OF CULTURED INTESTINAL TISSUE Final Rejection The Regents of the University of Michigan
17786255 CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELLS (CAR-DCS) AND METHODS OF MAKING AND USING SAME Final Rejection Washington University
18504261 GENE THERAPY FOR OCULAR DISORDERS Final Rejection The Trustees of the University of Pennsylvania
17937488 PHOSPHOGLYCERATE KINASE 1 (PGK) PROMOTERS AND METHODS OF USE FOR EXPRESSING CHIMERIC ANTIGEN RECEPTOR Non-Final OA The Trustees of the University of Pennsylvania
17995085 CHIMERIC ANTIGEN RECEPTORS TARGETING CD33 Non-Final OA Fred Hutchinson Cancer Center
18036909 MICROFLUIDIC-BASED BLADDER CANCER MIMIC AND USE THEREOF Non-Final OA CHUNG ANG UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
16960445 3D in vitro Models of Lung Tissue Non-Final OA THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
17769651 ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF Non-Final OA Fate Therapeutics, Inc.
17709565 NERVE CELL AND APPLICATION THEREOF Non-Final OA KEIO UNIVERSITY
17495597 MULTICELL CONJUGATES FOR ACTIVATING ANTIGEN-SPECIFIC T CELL RESPONSES Non-Final OA Wisconsin Alumni Research Foundation
17606489 ARTIFICIAL ANTIGEN PRESENTING CELLS COMPRISING LIGANDS FOR NKG2D FOR EXPANDING IMMUNE CELLS FOR IMMUNOTHERAPY Final Rejection H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
16321265 DIFFERENTIATED CELL PRODUCTION METHOD AND CULTURE BAG USED THEREFOR Final Rejection KYOTO UNIVERSITY
18227001 ADVANCED MANUFACTURED TRANSWELL USING SYNTHETIC BIOINK FOR CELL CULTURE AND IN VITRO TISSUE MODELS Non-Final OA Lung Biotechnology PBC
18354210 Methods for Differentiating Epithelial or Basal Cells Non-Final OA Lung Biotechnology PBC
18707061 COMPOSITIONS AND METHODS FOR USING INDIVIDUALIZED GENOME ASSEMBLIES AND INDUCED PLURIPOTENT STEM CELL LINES OF NONHUMAN PRIMATES FOR PRE-CLINICAL EVALUATION Non-Final OA EXIR LLC
17616200 USES OF NAD+ AND/OR NAD+ INHIBITORS AND/OR NAD+ AGONISTS AND COMBINATION PREPARATION THEREOF Final Rejection ShanghaiTech University
17997731 PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY Non-Final OA Iovance Biotherapeutics, Inc.
18050333 Methods of in Vitro Cell Delivery Non-Final OA Intellia Therapeutics, Inc.
17598916 METHOD FOR PRODUCING CAR GENE-INTRODUCED NK CELLS AND USE THEREOF Non-Final OA KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
18328598 NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF Non-Final OA Factor Bioscience Inc.
18278605 HUMAN FATTY-LIVER MODEL CELLS FOR USE IN SCREENING METHOD Non-Final OA PhoenixBio Co., Ltd.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month